BIONTECH SE-ADR (BNTX) Fundamental Analysis & Valuation

NASDAQ:BNTX • US09075V1026

Current stock price

105.46 USD
-0.1 (-0.09%)
At close:
104.281 USD
-1.18 (-1.12%)
After Hours:

This BNTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BNTX Profitability Analysis

1.1 Basic Checks

  • BNTX had negative earnings in the past year.
  • BNTX had a positive operating cash flow in the past year.
  • In multiple years BNTX reported negative net income over the last 5 years.
  • In the past 5 years BNTX always reported a positive cash flow from operatings.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -5.17%, BNTX belongs to the top of the industry, outperforming 84.69% of the companies in the same industry.
  • BNTX's Return On Equity of -5.91% is amongst the best of the industry. BNTX outperforms 88.57% of its industry peers.
Industry RankSector Rank
ROA -5.17%
ROE -5.91%
ROIC N/A
ROA(3y)-1.36%
ROA(5y)20.29%
ROE(3y)-1.58%
ROE(5y)25.77%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 100 150

1.3 Margins

  • With an excellent Gross Margin value of 83.31%, BNTX belongs to the best of the industry, outperforming 86.24% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
  • BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y-0.78%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BNTX Health Analysis

2.1 Basic Checks

  • BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BNTX has been increased compared to 1 year ago.
  • BNTX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for BNTX has remained at the same level compared to a year ago.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • BNTX has an Altman-Z score of 6.99. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 6.99, BNTX is doing good in the industry, outperforming 75.97% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.01, BNTX perfoms like the industry average, outperforming 45.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.99
ROIC/WACCN/A
WACC7.51%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • BNTX has a Current Ratio of 7.54. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
  • BNTX's Current ratio of 7.54 is fine compared to the rest of the industry. BNTX outperforms 69.19% of its industry peers.
  • BNTX has a Quick Ratio of 7.49. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
  • BNTX has a better Quick ratio (7.49) than 69.57% of its industry peers.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.49
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BNTX Growth Analysis

3.1 Past

  • The earnings per share for BNTX have decreased strongly by -69.06% in the last year.
  • The Revenue has been growing slightly by 4.32% in the past year.
  • BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.88% yearly.
EPS 1Y (TTM)-69.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.74%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y-45.07%
Revenue growth 5Y42.88%
Sales Q2Q%-23.75%

3.2 Future

  • Based on estimates for the next years, BNTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.65% on average per year.
  • BNTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.05% yearly.
EPS Next Y3.55%
EPS Next 2Y4.54%
EPS Next 3Y7.69%
EPS Next 5Y10.65%
Revenue Next Year-18.12%
Revenue Next 2Y-8%
Revenue Next 3Y-2.23%
Revenue Next 5Y6.05%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. BNTX Valuation Analysis

4.1 Price/Earnings Ratio

  • BNTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.54%
EPS Next 3Y7.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BNTX Dividend Analysis

5.1 Amount

  • BNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BNTX Fundamentals: All Metrics, Ratios and Statistics

BIONTECH SE-ADR

NASDAQ:BNTX (4/24/2026, 4:30:02 PM)

After market: 104.281 -1.18 (-1.12%)

105.46

-0.1 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-05
Inst Owners20.5%
Inst Owner Change-0.21%
Ins Owners1.15%
Ins Owner Change0%
Market Cap26.67B
Revenue(TTM)2.87B
Net Income(TTM)-1.14B
Analysts80
Price Target134.29 (27.34%)
Short Float %3.28%
Short Ratio3.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-257.36%
Min EPS beat(2)-559.15%
Max EPS beat(2)44.42%
EPS beat(4)3
Avg EPS beat(4)-118.52%
Min EPS beat(4)-559.15%
Max EPS beat(4)44.42%
EPS beat(8)5
Avg EPS beat(8)-22.37%
EPS beat(12)8
Avg EPS beat(12)159.41%
EPS beat(16)11
Avg EPS beat(16)126.26%
Revenue beat(2)2
Avg Revenue beat(2)37.32%
Min Revenue beat(2)19.58%
Max Revenue beat(2)55.06%
Revenue beat(4)4
Avg Revenue beat(4)36.85%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)6
Avg Revenue beat(8)23.99%
Revenue beat(12)6
Avg Revenue beat(12)6.75%
Revenue beat(16)9
Avg Revenue beat(16)10.93%
PT rev (1m)-4.6%
PT rev (3m)-3.67%
EPS NQ rev (1m)-5.94%
EPS NQ rev (3m)-1.5%
EPS NY rev (1m)-28.5%
EPS NY rev (3m)-37.34%
Revenue NQ rev (1m)-5.06%
Revenue NQ rev (3m)-15.79%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)-16.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.95
P/FCF N/A
P/OCF 50.01
P/B 1.19
P/tB 1.32
EV/EBITDA N/A
EPS(TTM)-5.5
EYN/A
EPS(NY)-5.3
Fwd EYN/A
FCF(TTM)-1.35
FCFYN/A
OCF(TTM)2.11
OCFY2%
SpS13.27
BVpS88.9
TBVpS79.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -5.17%
ROE -5.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.31%
FCFM N/A
ROA(3y)-1.36%
ROA(5y)20.29%
ROE(3y)-1.58%
ROE(5y)25.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y-0.78%
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 195.66%
Cap/Sales 26.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.49
Altman-Z 6.99
F-Score5
WACC7.51%
ROIC/WACCN/A
Cap/Depr(3y)244.04%
Cap/Depr(5y)246.52%
Cap/Sales(3y)20.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.74%
EPS Next Y3.55%
EPS Next 2Y4.54%
EPS Next 3Y7.69%
EPS Next 5Y10.65%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y-45.07%
Revenue growth 5Y42.88%
Sales Q2Q%-23.75%
Revenue Next Year-18.12%
Revenue Next 2Y-8%
Revenue Next 3Y-2.23%
Revenue Next 5Y6.05%
EBIT growth 1Y59.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.89%
EBIT Next 3Y5.3%
EBIT Next 5Y25.01%
FCF growth 1Y-19.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y119.55%
OCF growth 3Y-67.74%
OCF growth 5YN/A

BIONTECH SE-ADR / BNTX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIONTECH SE-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to BNTX.


What is the valuation status of BIONTECH SE-ADR (BNTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (BNTX). This can be considered as Overvalued.


Can you provide the profitability details for BIONTECH SE-ADR?

BIONTECH SE-ADR (BNTX) has a profitability rating of 4 / 10.


Can you provide the financial health for BNTX stock?

The financial health rating of BIONTECH SE-ADR (BNTX) is 5 / 10.